Bioprocess Technology Market is Anticipated to Rise USD 55.73 Billion by 2033 | At CAGR 6.65%
Ngày đăng: 27-01-2026 |
Ngày cập nhật: 27-01-2026
IMARC Group, a leading market research company, has recently released a report titled " Bioprocess Technology Market Trends , Share, size and Forecast by Product, Material, Distribution Channel, Pricing, End-User, and Region, 2025-2033." The study provides a detailed analysis of the industry, including the Bioprocess Technology market size, share, trends, and growth forecast. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Bioprocess Technology Market Overview
The global Bioprocess Technology Market was valued at USD 31.21 Billion in 2024 and is projected to reach USD 55.73 Billion by 2033. It is expected to grow at a compound annual growth rate (CAGR) of 6.65% during the forecast period of 2025-2033. Growth is driven by increasing demand for biologics, advancements in bioprocessing technologies, and expanding applications in cell and gene therapies.
Study Assumption Years
- Base Year: 2024
- Historical Year/Period: 2019-2024
- Forecast Year/Period: 2025-2033
- Current Market Size: USD 31.21 Billion in 2024
- CAGR: 6.65% (2025-2033)
- Forecast Period: 2025-2033
- North America dominates the market with over 44.5% share in 2024 due to advanced healthcare infrastructure and strong biopharmaceutical presence.
- Rising demand for pharmaceuticals including vaccines, monoclonal antibodies, and biosimilars are key growth drivers.
- Increasing adoption of single-use and continuous bioprocessing technologies boost production efficiency and reduce contamination risks.
- Regulatory support and escalating investments in R&D foster innovation in bioprocess technologies.
- Expansion of cell and gene therapies requires advanced bioprocessing solutions tailored to their unique manufacturing requirements.
Market Growth Factors
The growth of the bioprocess technology market is supported by the rising demand for pharmaceuticals such as vaccines, monoclonal antibodies, and biosimilars driven by increasing healthcare needs and prevalence of chronic diseases. For example, India’s pharmaceutical exports rose by 8.36% from $2.13 Billion in July 2023 to $2.31 Billion in July 2024, with expectations to reach $100 billion by 2025. Automation and improved bioprocessing equipment enhance production efficiency and scalability, while single-use technologies reduce contamination risks and operating costs. The growing market for regenerative medicine, cell and gene therapies, and biomanufacturing also contribute significantly to market expansion.
The United States market is propelled by advancements in single-use systems and automation, improving scalability and efficiency. Increased focus and investment in cell and gene therapies, supported by regulatory approvals, accelerate growth. Notably, in December 2024, New York’s first cell and gene therapy hub was opened at Roswell Park Comprehensive Cancer Center with a $98 million investment to foster research and treatment initiatives for solid tumors. These developments reflect the growing prominence of bioprocess technologies in addressing emerging health threats.
Innovations such as single-use bioreactors allow economical, flexible biopharmaceutical production while minimizing cleaning and sterilization costs. For instance, Getinge launched the AppliFlex ST GMP single-use bioreactor system in October 2023 aimed at enhancing clinical cell and gene therapy production. Continuous bioprocessing, exemplified by WuXi Biologics' November 2023 pilot-scale success using WuXiUPTM platform achieving ~6 g/L/day productivity, shortens processing times and lowers resource consumption. Market growth is further driven by automation, real-time analytics, and process intensification that improve product quality and manufacturing capacity worldwide.
Market Segmentation
By Product:
- Instruments
- Bioprocess Analyzers: Monitor, control, and optimize biological processes providing real-time data for efficient adjustments.
- Osmometers: Maintain consistent media osmolality essential for cell culture environments.
- Bioreactors: Central devices used for scaling up biological production processes.
- Incubators: Provide optimal environmental conditions for cell growth.
- Others: Not specifically detailed in the source.
- Consumables and Access
- Culture Media: Provide nutrients supporting cell and microbial growth.
- Reagents: Facilitate downstream processing like purification and quality testing.
- Others: Include additional materials associated with bioprocess workflows.
- Recombinant Proteins: Leading application due to their therapeutic, diagnostic, and industrial use especially in biopharmaceutical production.
- Monoclonal Antibodies: Used widely for treating chronic diseases and in biologics manufacturing.
- Antibiotics: Utilized in various therapeutic applications.
- Others: Not specified further in the source.
- Biotechnology and Biopharmaceutical Companies: Largest end users driven by biologics and advanced therapy development.
- Research and Academic Institutes: Engage in research and development of bioprocess technologies.
- Others: Not elaborated in the report.
North America is the dominant region with a market share exceeding 44.5% in 2024. The region benefits from advanced healthcare infrastructure, considerable investments in biotechnology research and development, and a strong presence of biopharmaceutical companies. The United States alone accounted for 89.00% of North America’s revenue in 2024. Regulatory support, adoption of single-use technologies, and extensive automation advancement reinforce this dominance.
Recent Developments & News
- December 2024: Sartorius Stedim Biotech opened its Center for Bioprocess Innovation in Marlborough, Massachusetts, to enhance collaboration and innovation in cell and gene therapy manufacturing.
- November 2024: New Wave Biotech launched the AI-powered Bioprocess Foresight platform to aid alt protein industry innovators with techno-economic and environmental impact analyses.
- October 2024: Croda Pharma introduced Super Refined™ Poloxamer 188, reducing shear stress in mammalian cell culture and supporting biologic development.
- July 2024: BioProcess360 Partners initiated a new investment fund to support emerging bioprocessing tools for traditional and novel drug modalities.
- July 2024: Nirrin Technologies released Atlas, a rapid at-line analysis system for biopharma, providing actionable data within one minute.
- June 2024: Pharmatec, a Syntegon subsidiary, unveiled the Modular Bioprocessing Platform, supporting microbial and mammalian cell culture with cost and time efficiencies.
- Advanced Instruments LLC
- Biopharma Dynamics Ltd.
- Danaher Corporation
- Hoffmann-La Roche AG
- Lonza Group AG
- Sartorius AG
- Thermo Fisher Scientific Inc.
- Univercells Technologies
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us
IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, considerations studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201971-6302
Thông tin liên hệ
: harryjoe
:
:
:
:
